Chemotherapy for small cell lung cancer
Combination chemotherapy has prolonged survival for patients with limited disease small cell lung cancer from a median of three months if untreated to 12 to 16 months and for those with extensive disease from one and a half months to six to 10 months.' Nevertheless, early hopes of chemotherapy resulting in a cure rate of 25% for those with limited disease have not been realised. Thus it is important to ask how many patients achieve long term survival, how toxic is the treatment, what are the long term side effects, and, finally, should all patients with small cell lung cancer be given chemotherapy?
Data from studies reporting results after two years of follow up after chemotherapy (or chemotherapy and radiotherapy) show that chemotherapy is most effective in patients who present with limited disease. In some series up to half have had a complete response (disappearance of all measurable disease) and nearly a third a partial response (reduction in tumour size of half or more lasting for at least one month). In patients who have presented with widespread disease a quarter have had a complete response and half a partial response. The achievement of a complete response is the main determinant of long term survival. Data from nine studies were recently reviewed and the overall survival rate at two years calculated as 7%. 4 Not all patients who survive for two years remain free of tumour. A review of 225 patients treated with chemotherapy and irradiation at the National Cancer Institute showed that 28 patients were free of disease 30 months or more after starting treatment. Thirteen of these subsequently relapsed, eight with small cell lung cancer 31-74 months from diagnosis, three with other malignancies, and two with unknown causes.'4 A disturbing finding in the 15 survivors who were free of disease was that five had abnormal mental states, four had abnormal computed tomographic brain scans with evidence of cortical atrophy, and seven were unable to resume their occupation. Thus about half of the long term survivors had either some form of disease or limitation of lifestyle related to previous treatment, in addition to running the risk of relapse.'4 A similar review from the MD Anderson Hospital identified 43 patients alive at three years. Eleven of these subsequently relapsed, and death from unrelated causes was documented in another three.'5 Among the survivors three had severe neurological symptoms including dementia and ataxia, although nine had minor complaints only and 17 remained well.'5 Whether prophylactic cerebral irradiation-which reduces and delays the incidence of cerebral metastases-is an important determinant of the cerebral deterioration is not known. Undoubtedly the development of the "central nervous system syndrome," with loss of memory, tremor, somnolence, slurred speech, and myoclonus as a possible long term effect of treatment, is a cause for concern, though it has not been reported in all studies of long terrn survival.'6 1 The benefits of prophylactic cranial irradiation, VOLUME 290 NO 6466 PAGE 413 given as a routine to patients who respond, have not been shown to outweigh the long term disadvantages.
Thus the treatment of patients with small cell lung cancer remains difficult, and in dealing with an aging population (the mean age in most studies has been between 55 and 65) the potential toxicity of treatment must be weighed against the potential for improved survival rates and possible long term survival. There have been few studies assessing quality of life, but in patients who presented with symptoms (as most do) such as anorexia, loss of weight, malaise, haemoptysis, bone pain, or obstruction of the superior vena cava, nearly three quarters had their symptoms relieved by three months, or four courses, of chemotherapy.'8 The optimal duration of chemotherapy is being investigated. The benefits from treatment seem to occur early and side effects tend to occur later, becoming more noticeable as treatment is prolonged. Data on long term survival suggest that 12 to 18 months' treatment is necessary, but whether this is the optimum duration of treatment is not known, and recent studies of shorter treatment regimens with three and six courses of chemotherapy followed by chest irradiation have shown no difference in median survival. '9 Current studies should show whether all patients with small cell lung cancer should be treated similarly or whether shorter courses of chemotherapy are more appropriate for giving symptomatic relief in patients with extensive and usually incurable disease. Long term survival occurs in 10-15% of patients with limited disease, minimal symptoms, small tumour volume, and other favourable prognostic factors. Nevertheless, the optimal duration of chemotherapy, the place of additional radiotherapy, the cause of late neurological sequelae, and the value of further chemotherapy to treat long term survivors who relapse have yet to be defined. Thus further work is needed if we are to improve our management of this aggressive disease.
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Consultant Physician, Brompton Hospital, London SW3 6HP Platelets and coronary disease, round three A fresh thrombus consists of masses of platelets stuck to each other, supported by a mesh of fibrin strands. Arterial thrombosis usually occurs in association with an atheromatous plaque, and it seems likely that the development of plaque is the result of repeated thrombotic episodes.' Thus platelets may have an important role in arterial disease and in the sudden clinical events, such as myocardial infarction, that accompany it. Furthermore, it seems reasonable to expect that patients with arterial disease or thrombosis would have stickier platelets than healthy subjects, and many tests of platelet function have been devised to test this hypothesis.
On page 428 Dr T W Meade and his colleagues describe an epidemiological study of what they call platelet aggregability. The technique they used is a modification of Born's optical density method,2 which measures changes in the transmission of light through platelet rich plasma as platelets form clumps in response to the addition of aggregating agents such as adenosine diphosphate. In this modified method 10 concentrations of adenosine diphosphate are tested to estimate the maximum velocity of the change in the transmission of light (which corresponds to the maximum rate of clump formation) and from this the ED50, or estimated dose of adenosine diphosphate that causes half the maximum response, is calculated.
The platelet aggregability of 958 subjects was studied, of whom 24 had a history of ischaemic heart disease and 54 evidence of ischaemia in the electrocardiogram. In some respects aggregability followed the same trends as the risk factors for coronary disease-for example, it increased with age-but in others it did not, being less marked in men than women and not increased by smoking or by oral contraceptives. The range of ED50 was wide, and, although patients with coronary disease had more aggregable platelets than healthy controls, the difference was not significant. This may have been because there were few subjects with coronary disease, and it would be helpful to know what would be found if the study was repeated on a larger group of patients with age and sex matched control subjects. The observations are, however, consistent with the prevalent view that, though there is a difference in platelet behaviour between groups of healthy subjects and groups of patients with coronary disease, it is not possible to show specific platelet abnormalities in individual patients.3 This concept represents round three of the platelet and thrombosis story.
Born's original aggregation method was designed to study the formation of clumps of platelets in a test tube. Differences between groups of patients and healthy subjects were shown,4 but the technique was never found to be useful for identifying individual subjects with vascular disease. In round one of the platelet and vascular disease story, which took place in the early 1960s, many other tests of platelet function were used and measurements of platelets in whole blood sticking
